J&J Q3 Beat Overshadowed by Medtech Miss; Shares Drop 5%
JNJ sits 35% above its 52-week low of $184.66 on elevated volume (2.4× avg).
Summary
J&J beat Q3 estimates with adjusted EPS of $2.59, but shares fell over 5% as medtech growth of 2.5% lagged the 7.7% drug growth. Medtech sales of $8.64B missed expectations, with CFO Joe Wolk blaming Gulf defense spending shifts, European austerity, and China pricing pressure. The company plans to spin off DePuy Synthes by mid-2027 and will detail the plan and 2027 guidance at a Dec. 8 investor event. This follows the July guidance cut tied to the Firefly Bio acquisition and the $5.5B talc settlement, adding to a year of mixed signals. The medtech weakness is the key new negative, as it offsets the pharma strength that had been driving the stock.
At the time of this announcement, JNJ was trading at $249.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $599.1B. The 52-week trading range was $184.66 to $281.07. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Binance News.